Piper Sandler on Supernus Pharmaceuticals (SUPN): Sage Purchase A Head-Scratcher
Tweet Send to a Friend
Piper Sandler analyst David Amsellem reiterated a Neutral rating and $36.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
